INTRODUCTION

Chronic wounds, which is defined as no measurable healing progress (20-40% reduction in the area) after 2-4 weeks of optimal treatment, are associated with increased morbidity and mortality and poses a serious economic burden on the healthcare system. It has been estimated that nearly $25 billion are spent annually in the United States to treat...
ulcers. Therefore, it is highly desirable to promote the acceleration of wound healing, which would improve patients’ quality-of-life and reduce the economic impact on the health-care system.

Underlying confounding factors such as old ages, diabetes mellitus, microcirculation impairment, systemic hypoxia, atherosclerosis and malnutrition causes chronic wound. Several novel approaches have been proposed for treatment of recalcitrant wounds according to the wound healing mechanism. These are the use of stem cells, platelet-derived growth factors, fibrin glue and each of these approaches has been reported to improve healing in chronic wounds.

Deep sternal wound infection (DSWI) is a dangerous complication of cardiac surgery with a frequency rate from 0.2% up to 8% and a mortality rate from 5% up to 50%. Therapeutic options include debridement with early or delayed closure, closed continuous irrigation, negative pressure wound therapy and partial or complete sternectomy with flap reconstruction, but there is still a general lack of a standard treatment protocol.

Considering the high mortality rate, there is an urgent need for developing further treatment procedures; and in the first approach, a non-invasive method is highly desirable.

In this study, we report on the first six patients included in a clinical trial aiming to evaluate the treatment of chronic sternal wounds using a combined application of platelets and fibrin glue (PFG) where conventional treatment methods (surgical debridement, bacterial balance and moisture balance at least for 4 weeks) have failed.

**MATERIALS AND METHODS**

Six patients with recalcitrant sternal wounds that did not respond to conventional therapy and their life at risk were included. The conventional therapy was surgical debridement, complementary treatment (such as antibiotic therapy, blood glucose level control, administration of zinc sulphate and multivitamins and irrigation of wound with normal saline) and moisture balance (wet-to-moist dressings) at least for 4 weeks.

The study protocol were reviewed and approved by the Human Research Ethics Committee of Mashhad University of Medical Sciences (Mashhad, Iran). Informed consent was obtained from the patient. Inclusion criteria were the presence of a recalcitrant wound, agreement of the patient to comply with the protocol requirements (after every 2 day washing the wounds and applying combined application of PFG) also self-care of wounds and strict compliance to all follow-up visits. Exclusion criteria were pregnancy, active or previous (within 8 weeks of the study screening visit) chemotherapy, current participation in another clinical investigation, current candidates for vascular surgery, angioplasty or stenting, patients presenting with the clinical characteristics of cellulitis at the ulcer site, purulence or sinus tracts that could not be removed by debridement of the wound to be treated, malignant wounds, vasculitis or connective tissue disease, bone marrow involvement (lymphoma — leukaemia) patients treated with corticosteroids, lactating mothers and patients with any systemic infection, malnutrition, microcirculation impairment and systemic hypoxia.

During the platelets preparation in the Blood Transfusion Organisation in Mashhad, Iran, some units had to be discarded due to contamination of platelets unit with red blood cells, which cannot be transfused to the patients, but they passed all viral safety tests according to blood transfusion regulation.

From 400 ml peripheral blood, 25 ml platelet-rich plasma (PRP) was prepared from ABO match donor. A total volume of 25 ml of concentrated fibrinogen was prepared from separated plasma by two biochemical method either cryoprecipitate method or ethanol precipitation method, then mixed with PRP (final volume 50 ml: Platelet-fibrinogen rich plasma [PFRP]). One millilitre of thrombin was prepared from removed plasma by adding 10% calcium gluconate. Viral inactivation was done for PFRP and thrombin (1 h at 62°C) and frozen in-20°C freezer until use, for a maximum of 3 months. Prior to the application of PFRP, the area of necrotic and devitalized wound was debrided surgically until bleeding was recognized macroscopically. This allowed the PFRP to come into contact with viable wound tissue. In time of using PFRP, 50 ml was mixed with 1 ml thrombin and calcium gluconate and PFG placed on the wound. Finally, paraffin gauze pads were placed over the wound and a bolster of rolled gauze pads placed over the paraffin gauze. This dressing was then wrapped with rolled gauze. After 2 days, the entire dressing was removed and the wound irrigated with isotonic sodium chloride solution. The wound was treated as described above, after every
2 days again for the formation of granulation tissue and closure. The patients were followed up regularly for ulcer closure and any other possible complications. Digital camera pictures were taken on day 0 and every three weeks, until healing. Ulcer dimensions (length, width, depth) were measured on day 0. The endpoint of follow-up was the closure of the wound after topically application of PFG. The antibiotic therapy was based on the antibiogram of the wound swabs.

RESULTS

The patients' characteristics, past medical history, wound size and duration of wound are presented in Table 1. After treatment, the wound was completely closed in 5 patients (100% healing) and significantly reduced in 1 patient (50% healing). Mean age 55.35 ± 9.98 years, 71.5% were male.

Mean healing time (100% healing) for five patients were 16 ± 3.1 weeks. There was no evidence of local or systemic complications and any abnormal tissue formation, keloid, or hypertrophic scarring. Pictures of the wounds, before and after treatment of selected patients are presented in Figures 1 following the same numerical order as in Table 1.

DISCUSSION

In this pilot study, six patients with sternal chronic wound, which did not responded to conventional therapy, were treated with a combination allogenic PFG. After treatment, wounds of five patients were completely closed and in one patient, wounds significantly improved. The appearance of ulcer bed was bleeding during dressing changes and ulcer palpation was noted and considered as a positive indicator for wound healing.

In this study, the rational beyond using PRP is the replenishment of the significantly decreased local concentration of bioactive factors, in chronic wound. In platelets, bioactive factors are in the α-granules and the dense granules. The α-granules contain growth factors such as transforming growth factor-β, platelet-derived growth factor, insulin-like growth factor, fibroblast growth

| Patient no. | Age (years)/gender | Past medical history/ atherosclerosis risk factor | Reason of surgery (CABG, MVR, VSD, etc.) | Length, width, depth (cm) in the sternum | Bacteria isolation from wound | Weeks of treatment and healing situation |
|-------------|--------------------|-----------------------------------------------|----------------------------------------|----------------------------------------|-----------------------------|----------------------------------------|
| 1.          | 62/M               | Diabetes mellitus, HLP, HTN                    | 3VD                                   | 9×1.5×2                                | Staphylococcus aureus       | 12 healed                             |
| 2.          | 35/F               | Congenital heart disease                      | Congenital VSD                         | 8×3×1                                  | Mix growth                  | 16 improvement >50%                   |
| 3.          | 57/M               | Diabetes mellitus, HLP                        | 3VD                                   | 9×7×1                                  | Gram-negative bacilli       | 20                                     |
| 4.          | 60/M               | HLP, HTN, heavy smoker                        | 3VD                                   | 9×3×1.5                                | No growth                   | 18                                     |
| 5.          | 66/M               | Diabetes mellitus, dialysis patient, insulin injection | LM, LAD                              | 8×5×1                                  | No growth                   | 16                                     |
| 6.          | 47/F               | Diabetes mellitus                             | LM, LAD                                | 5×4×3                                  | Staphylococcus aureus       | 14                                     |

M: Male, F: Female, HLP: Hyperlipidaemia, HTN: Hypertension, 3VD: Three vessels disease, 2VD: Two vessels disease, LM: Left main coronary artery, LAD: Left anterior descending, Diabetes mellitus: Non-insulin dependent diabetes mellitus (NIDDM), Heavy smoker: 20 cigarettes/day, MVR: Mitral valve replacement, CABG: Coronary arteries bypass graft, VSD: Ventricular septal defect

Figure 1: Wounds treatment outcome with a combination of allogenic platelet-rich plasma and fibrin glue
factor, epidermal growth factor, vascular endothelial growth factor, and endothelial cell growth factor. The dense granules contain non–growth factors such as serotonin, histamine, dopamine, calcium, and adenosine. These factors play important roles in wound healing.\[8,9\] In addition, platelets have antimicrobial activity.[10,11]

The rationale behind using fibrin glue that it behaves as a provisional matrix and actively recruits cells to trigger fibrin-mediated responses, such as cell adhesion, migration, proliferation and tubule formation. Fibrin promotes cell growth and vessel formation, which are beneficial during wound repair.[12]

In this study, the patients who needed a long term treatment with platelets, required large volumes of blood and aspiration of such volumes from patients was impossible and therefore, allogenic platelets were replaced. Although, all safety tests were performed for blood bank products, but was on alert on safety concerns. In addition to negative viral tests for platelets, which used for the patients, viral deactivation was performed by heating.

Kachel treated a DWSI by injection of allogenic platelet gel into the wound. Also, few studies in cardiac surgery, applied autologous platelet gel on the wound surface area at the end of the operation as prophylaxis against wound infection rather than as therapy for established DSWI.[8] PFG has been applied for treatment of other chronic wounds In a retrospective cohort study on the effectiveness of autologous platelet releasate in the treatment of diabetic neuropathic foot ulcers, Margolis et al. showed that platelet releasate was more likely to be used in more severe wounds and was also more effective in treating these wounds than the standard of care.[13]

In a prospective non-blinded study, Crovetti et al. showed the efficacy of once-weekly applications of either autologous or homologous origin platelet gel in healing cutaneous chronic wounds. Nine patients had healed completely and nine had responded partially.[14]

In a prospective, randomized, controlled multicenter trial, Driver et al. reported the use of autologous PRP for the treatment of diabetic foot ulcers. The authors found that 68.4 percent of patients in the PRP group and 42.9 percent of patients in the control group had wounds that healed.[15]

In a prospective trial, Jeong et al. achieved the complete wound healing in 79 percent of the blood bank platelet concentrate-treated group and 46 percent of the control group (P < 0.05). The times required for complete healing were 7.0 ± 1.9 and 9.2 ± 2.2 weeks in the blood bank platelet concentrate-treated and control groups, respectively (P < 0.05). No adverse events related to the study treatment occurred.[16]

In a pilot study, Chen et al. evaluated the safety and efficacy of combining allogenic single-donor PFG to enhance skin graft take for treating ulcers. He found that the most skin grafts took well. No adverse reactions and recurrence of ulcers was noted during the 3- to -18-month follow-up period.[17]

In a case report, Sell et al. treated chronic stage IV pressure ulcers, in three veterans with spinal cord injury, with a sustained release PRP therapy to stimulate wound healing. PRP treatment consistently resulted in the formation of granulation tissue and improved vascularity for each of the three patients treated, while reducing the overall ulcer area and volume.[18]

CONCLUSION

Our results demonstrated the feasibility of our operational model as a non-invasive method as the first approach for treatment chronic sternal wounds. The PFG healed or significantly reduced the wound size in sternal wounds. There was no evidence of local or systemic complications related to the procedure. Based on these results, we are conducting a larger study with the aim of further evaluations of PFG therapy in the treatment of chronic sterna wound.

ACKNOWLEDGEMENT

This research project was supported by the Mashhad University of Medical Science Research Council.

REFERENCES

1. Sharma RK, John JR. Role of stem cells in the management of chronic wounds. Indian J Plast Surg 2012;45:237-43.
2. Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, et al. Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair Regen 2009;17:763-71.
3. Harding KG, Morris HL, Patel GK. Science, medicine and the future: Healing chronic wounds. BMJ 2002;324:160-3.
4. Ravari H, Hamidi-Almadari D, Salimifar M, Bonakdar S, Parizadeh MR, Koliakos G. Treatment of non-healing wounds with autologous bone marrow cells, platelets, fibrin glue and
5. Schimmer C, Sommer SP, Bensch M, Leyh R. Primary treatment of deep sternal wound infection after cardiac surgery: A survey of German heart surgery centers. Interact Cardiovasc Thorac Surg 2007;6:708-11.
6. Juhl AA, Koudahl V, Damsgaard TE. Deep sternal wound infection after open heart surgery — Reconstructive options. Scand Cardiovasc J 2012;46:254-61.
7. Silver FH, Wang MC, Pins GD. Preparation and use of fibrin glue in surgery. Biomaterials 1995;16:891-903.
8. Kachel E, Callum J, Moussa F, Goldstein J, Frenes S. Treatment of deep sternal wound infections after coronary artery bypass grafting by means of injection of platelet gel: An evolving technology. J Thorac Cardiovasc Surg 2010;139:e118-20.
9. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: From basic science to clinical applications. Am J Sports Med 2009;37:2259-72.
10. Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Krol W, Wielkoszynski T. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: An in vitro study. J Bone Joint Surg Br 2007;89:417-20.
11. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002;70:6524-33.
12. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006;4:932-9.
13. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001;24:483-8.
14. Crovetti G, Martinelli G, Issi M, Barone M, Guizzardi M, Campanati B, et al. Platelet gel for healing cutaneous chronic wounds. Transfus Apher Sci 2004;30:145-51.
15. Driver VR, Hanft J, Fylling CP, Beriou JM, Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006;52:68-70, 72, 74 passim.
16. Jeong SH, Han SK, Kim WK. Treatment of diabetic foot ulcers using a blood bank platelet concentrate. Plast Reconstr Surg 2010;125:944-52.
17. Chen TM, Tsai JC, Burnouf T. A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers. Dermatol Surg 2010;36:453-60.
18. Sell SA, Eriksen JJ, Reis TW, Droste LR, Bhuiyan MB, Gater DR. A case report on the use of sustained release platelet-rich plasma for the treatment of chronic pressure ulcers. J Spinal Cord Med 2011;34:122-7.

How to cite this article: Tashnizi MA, Alamdari DH, Khayami ME, Rahimi HR, Moeinipour A, Amouzeshi A, et al. Treatment of non-healing sternum wound after open-heart surgery with allogenic platelet-rich plasma and fibrin glue-preliminary outcomes. Indian J Plast Surg 2013;46:538-42.

Source of Support: This research project was supported by the Mashhad University of Medical Science Research Council.

Conflict of Interest: None declared.

Announcement

Android App

A free application to browse and search the journal’s content is now available for Android based mobiles and devices. The application provides “Table of Contents” of the latest issues, which are stored on the device for future offline browsing. Internet connection is required to access the back issues and search facility. The application is compatible with all the versions of Android. The application can be downloaded from https://market.android.com/details?id=comm.app.medknow. For suggestions and comments do write back to us.